CCK antagonists promote apoptosis in glioma cells by increasing caspase 3 activity [49], and the antagonist of the ETB receptor BQ788 inhibits the proliferation of oligodendroglioma cells and increases survival [52]. Here, CASP3 is linked to central nervous system cancer.